Group 1 - The Nipah virus outbreak has been reported in West Bengal, India, with 5 confirmed cases, including healthcare workers, and one patient in critical condition [2] - The local government is taking measures to contain the virus spread, including home isolation for nearly 100 individuals and testing bats in local zoos [2] - Thailand's Civil Aviation Authority announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [3] Group 2 - In the A-share market, stocks related to vaccines, influenza, and biotechnology surged, with companies like Maike Biological, Cap Bio, and others hitting a 20% limit up [4] - The Wind popular concept index shows significant increases in vaccine-related stocks, with a rise of 6.59% [5] - Investors are inquiring about listed companies with products related to the Nipah virus on platforms like Shenzhen Stock Exchange Interactive and Shanghai Stock Exchange Interactive [5] Group 3 - The World Health Organization describes the Nipah virus as a zoonotic virus that can be transmitted from infected animals to humans, with a mortality rate typically over 40% [8] - Symptoms of human infection include acute respiratory infections and potentially fatal encephalitis, with an incubation period ranging from 4 to 14 days, and up to 45 days in some cases [8]

Market Overview - The A-share market experienced fluctuations on January 26, with the Shenzhen Component Index and the ChiNext Index both declining over 1% during the day. The Shanghai Composite Index closed down 0.09%, the Shenzhen Component Index down 0.85%, and the ChiNext Index down 0.91% [1][2] - The total market turnover reached 3.28 trillion yuan, an increase of 162.5 billion yuan compared to the previous trading day, with over 3,700 stocks declining [1][2] Gold and Precious Metals - Gold prices surged, breaking the 5,100 USD/oz mark for the first time, reaching a high of 5,110.26 USD/oz. Silver also saw significant gains, with prices peaking at 109.453 USD/oz, marking an increase of over 51% in just 17 trading days [4][9] - The rising gold prices have led to a substantial increase in market demand for gold investment and storage, resulting in a booming demand for bank safe deposit boxes. For instance, at the Shenzhen branch of China Merchants Bank, all 8,000 safe deposit boxes are fully rented, with 500 to 600 customers waiting to rent a box, which could take 5 to 6 years based on the current turnover rate [4][9] Vaccine Sector - The flu vaccine sector saw a strong performance, with stocks such as Da An Gene, Hualan Biological Engineering, and Zhijiang Biological all hitting the daily limit. Yongshun Biological surged over 27%, while other companies like Oriental Bio and Zhongsheng Pharmaceutical also experienced gains [4][5] - The vaccine index rose by 6.79%, indicating a positive trend in the sector [5] Oil and Gas Sector - The oil and gas sector showed strength, with China National Offshore Oil Corporation reaching a historical high. Other companies like Intercontinental Oil and China Petroleum saw increases of over 5% [7] - The space photovoltaic sector also remained active, with stocks like Mingyang Smart Energy and Tuojin New Energy hitting the daily limit [7] Tencent Cloud and AI Applications - Tencent's cloud concept saw some activity, with stocks like Qunxing Toys hitting the daily limit and Ruijie Networks rising over 10%. Tencent announced the launch of a cash red envelope event for its AI assistant app, which is expected to drive engagement [7]

Core Viewpoint - The A-share market saw a significant rise in vaccine stocks due to the outbreak of the Nipah virus in West Bengal, India, which has a high mortality rate and no available vaccine [1] Group 1: Market Performance - Vaccine stocks such as Hualan Biological, Gendik, and Zhifei Biological experienced substantial gains, with Gendik hitting the 20% limit up, Zhifei Biological rising over 15%, and Kangle Health increasing by over 13% [1] - Other notable increases included CanSino Biologics up by over 12%, Watson Biotech by over 10%, and Kangtai Biological by over 7% [1] Group 2: Company Specifics - Gendik acknowledged awareness of the Nipah virus news but stated that the company does not have related products [1] - The total market capitalization of leading vaccine companies includes Zhifei Biological at 477 billion, Watson Biotech at 230 billion, and CanSino Biologics at 192 billion [2]

今日午后开盘，疫苗概念快速拉升，疫苗、生物医药、创新药等细分领域表现亮眼，截至发稿，疫苗 ETF富国（159645）盘中涨3.87%，其成分股华兰疫苗涨20%，万孚生物涨超17%，智飞生物涨超13%。 消息面上，华兰疫苗发布公告，公司重组带状疱疹疫苗于近日获得国家药品监督管理局颁发的药物临床 试验批准通知书，获准开展临床试验。该进展被视为公司在重要预防领域管线布局的关键突破。市场预 期随着国内老龄化进程加快，带状疱疹疫苗接种需求增长空间较大。 疫苗ETF富国（159645）紧密跟踪国证疫苗与生物科技指数（980015）指数，指数由业务涉及生物科技 产业的50家A股上市公司组成，反映A股市场的生物科技产业中优质上市公司的整体表现，帮助投资者 精准捕捉医疗疫苗领域投资机会。 （文章来源：每日经济新闻） 相关机构表示，长期来看，疫苗渗透率提升叠加人口老龄化进程加快，如带状疱疹疫苗接种需求增长空 间较大。而国内创新型疫苗的加速审批上市、鼓励疫苗研发投入加大等相关政策的陆续发布，也将推动 我国疫苗行业快速发展。此外，疫苗出海也为疫苗行业拓宽了需求领域，近期海外如印度西孟加拉邦暴 发尼帕病毒疫情也引发关注。 ...

Group 1 - Vaccine-related stocks have shown strong performance, with Zhifei Biological rising over 16%, Watson Bio increasing by more than 11%, and Kangtai Biological up by over 8% [1] - The vaccine-related ETFs have also experienced a rise of approximately 4% [1] Group 2 - Specific ETF performance includes: - Vaccine ETF from Fuguo at 0.727, up by 0.029 (4.15%) - Vaccine ETF from Penghua at 0.705, up by 0.028 (4.14%) - General Vaccine ETF at 0.642, up by 0.023 (3.72%) [2] - Institutions indicate that the long-term growth potential for vaccine demand is significant due to increasing vaccination penetration and an aging population [2] - The acceleration of approval and market entry for innovative domestic vaccines, along with increased investment in vaccine research and supportive policies, is expected to drive rapid development in China's vaccine industry [2]

人民财讯1月26日电，沪指早间窄幅震荡，深证成指、创业板指走低。截至午间收盘，沪指涨0.12%， 深证成指跌0.74%，创业板指跌0.86%。盘面上，黄金概念持续走强，湖南黄金、盛达资源、四川黄 金、中国黄金等多股涨停；疫苗概念活跃，华兰疫苗20%涨停。此外，采掘、保险、有色金属、石油、 小金属、化肥等板块涨幅居前；航天航空、汽车零部件、游戏、半导体、家用轻工、商业航天、机器人 执行器概念等板块跌幅居前。全市场超1600只个股上涨，上午半天成交超2万亿元。 ...

Core Insights - Fang Xinxia is recognized as a leading figure in international capital, transitioning from a Hong Kong youth to a global investment leader, achieving significant wealth accumulation and market influence [1][4] - The article highlights Fang's strategic focus on A-shares since 2019, emphasizing trend analysis and policy benefits, while accurately predicting market movements in Hong Kong [1][9] Education Background - Doctorate in Business Administration from Atlanta University, focusing on global capital flows and emerging market opportunities [1][2] - MBA from California International University, specializing in cross-cultural enterprise management [2] - Bachelor's degrees in hotel, gaming, and beverage management from the University of Nevada, Las Vegas, providing insights into consumer psychology [3] Investment Journey - **Initial Wealth Accumulation (2002–2009)**: Achieved significant earnings through sneaker trading and eBay, with a peak monthly profit of 7 million HKD in 2005 [6] - **Business Empire Development (2013–2018)**: Founded FSH CLUB and established a reputation as a "young stock god," generating substantial profits [7][8] - **A-share Focus and Market Predictions (2019–2025)**: Shifted to A-shares, predicting systemic risks in Hong Kong's retail and tourism sectors, and achieving notable returns in sectors like AI and renewable energy [9][10] Recognition and Honors - Featured multiple times in media, recognized as a significant figure in the investment community, and awarded titles such as "Annual Influential Figure in China's Capital Market" [11] Philanthropy and Publications - Engaged in charitable activities, including building schools and initiating a public donation program, raising over 30 million HKD [14] - Authored several influential investment books, with notable sales and impact on investment education [15] Investment Philosophy - Emphasizes the importance of cognitive understanding over capital, prioritizing macroeconomic data for market direction, and maintaining a disciplined risk management approach [16]

Group 1 - The vaccine sector continues to strengthen, with Jindike's stock hitting the daily limit increase of 20% [1] - Other companies in the vaccine industry, such as Hualan Biological Engineering, Baike Biotechnology, Shuanglu Pharmaceutical, Kangtai Biological, Bohui Innovation, and Watson Biotech, also experienced stock price increases [1]

Market Overview - The main indices showed a decline today, with the Shanghai Composite Index down by 0.81%, the Shenzhen Component down by 1.14%, and the ChiNext Index down by 2.31% [1] - In terms of industry performance, the pharmaceutical and biological, media, and retail sectors led the gains, while non-bank financials, public utilities, and defense industries lagged behind [1] Concept Sector Performance - Overall, the lithium battery electrolyte, innovative drugs, and vaccine concepts performed relatively well, whereas rare earths, memory storage, and large-scale infrastructure state-owned enterprises showed weaker performance [1]

Core Viewpoint - Wante Bio's stock price has experienced a decline of 18.10% year-to-date, with recent fluctuations indicating a slight recovery in the short term [1] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [1] - The main revenue composition includes diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active ingredients (0.76%) [1] Financial Performance - As of June 30, 2025, Wante Bio reported a revenue of 844 million yuan, a year-on-year decrease of 38.25%, and a net profit attributable to shareholders of -144 million yuan, a year-on-year decrease of 155.30% [2] - Cumulative cash dividends since the A-share listing amount to 1.541 billion yuan, with 1.311 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 24.00% to 38,400, while the average circulating shares per person decreased by 19.36% to 32,958 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 22.7544 million shares, an increase of 5.1508 million shares from the previous period [3]